Study to Evaluate the Effect of Single Doses of LX4211 and Canagliflozin on Intestinal Glucose Absorption in Healthy Adult Subjects

Inclusion Criteria: * Adult subjects ≥18 to ≤55 years of age * Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mmHg; diastolic blood pressure, 50-90 mmHg; heart rate, 45-100 bpm * Body mass index (BMI) ≥18 and ≤35 kg/sq m * Willing and able to provide written informed consent Exclusion Criteria: * Use of any medication (prescription, over-the-counter, herbal tea, or supplements) within 7 days of dosing * Use of any investigational agent or study treatment within 30 days of Day -1 * Use of any protein or antibody-based therapeutic agents within 3 months of Screening * Prior exposure to LX4211 or canagliflozin * Daily use of \>5 cigarettes or any tobacco products within 6 weeks prior to Screening and while participating in the study * History of bariatric surgery or any other gastrointestinal surgery that may induce malabsorption * History of bowel resection, any malabsorptive disorder, severe gastroparesis, any GI procedure for the purpose of weight loss which would slow gastric emptying * History of any major surgery within 6 months prior to Screening * History of any hypersensitivity to the inactive components of LX4211, inactive components of canagliflozin, acetaminophen oral solution or any inactive component of acetaminophen liquid preparation * History of renal disease or significantly abnormal kidney function tests * History of hepatic disease or significantly abnormal liver function tests * History of any active infection within 30 days prior to Day -1 * History of alcohol or substance abuse within 2 years prior to Day 1 * History of hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab), HIV-1 or HIV-2 * Donation or loss of \>500 mL of blood or blood product within 56 days of Day -1 * positive pregnancy test at Screening or Day -1 * Positive urine screen for drugs of abuse at Screening or Day -1 * Positive breath test for alcohol at Screening or Day -1 * Inability or difficulty swallowing whole tablets * Unable or unwilling to communicate or cooperate with the Investigator